top of page

This month’s elections put Republicans back in control of the U.S. House of Representatives, raising questions about the prospects of marijuana reform in the next Congress.

In recent years it has been repeatedly shown that cannabis legalization and smaller, incremental reforms such as banking access have majority support to pass. But whether marijuana legislation advances or stalls in the next two years will largely come down to whether those who are in leadership allow the measures to even be brought up for votes.

The full House still needs to formally elect a new speaker at the start of the new Congress in January, but the Republican caucus has already made their picks for top leadership positions. Democrats, meanwhile, have yet to hold a caucus election to fill the top spots for the 118th Congress, but members appear to be rallying around a new generation of expected incoming leaders.

While not all decisions have been finalized yet, there aren’t expected to be any major surprises. So here’s a look at where the key lawmakers in both parties stand on marijuana and other drug policy reform:

Republicans

House Speaker

Current House Minority Leader Kevin McCarthy (R-CA) was nominated by his GOP colleagues earlier this month to be elected as speaker. While it remains to be seen whether he can get a majority of at least 218 votes on the floor in January to officially get the job, McCarthy’s prospective election is not an especially ideal scenario for legalization advocates, as he’s opposed various reform proposals—though he did vote for a bipartisan cannabis banking bill twice.

McCarthy voted against the House-passed Marijuana Opportunity, Reinvestment and Expungement (MORE) Act to legalize marijuana earlier this year, and he’s also opposed multiple amendments to provide protections for state-legal recreational, medical and CBD-only cannabis programs.

This week, your House Democrat majority is tackling the tough issues by holding a vote on legalizing pot and banning tiger ownership.

Nothing for small businesses. Nothing for re-opening schools. Nothing on battling the pandemic.

Just cannabis and cats.

— Kevin McCarthy (@GOPLeader) November 30, 2020


He blasted Democrats in 2020 over scheduling a vote on the legalization bill, saying that the party was “picking weed over the workers” and “picking marijuana over the much-needed money we need to go forward, the small businesses that are closing” amid the pandemic.

The congressman voted against legislation to let U.S. Department of Veterans Affairs (VA) doctors to recommend medical cannabis to veterans, retroactively make it so cannabis could not be used as the basis of denying federal workers a security clearance and remove research barriers into Schedule I drugs including marijuana and certain psychedelics.

McCarthy voted in favor of a controversial proposal to remove language of a spending bill providing protections against the loss of federal funding for universities that study cannabis. That amendment was ultimately rejected last year.

However, he did vote for a bipartisan cannabis research bill in April that recently cleared the Senate, making it the first-ever piece of standalone marijuana reform legislation to be sent to the president’s desk.

McCarthy has also twice voted in support of the Secure and Fair Enforcement (SAFE) Banking Act to protect banks that work with state-legal marijuana businesses from being penalized by federal regulators. That’s despite the fact that he curiously criticized Democrats for including the reform in a coronavirus relief package in 2020.

The Democrats’ $3 trillion dollar wishlist mentioned the word “cannabis” more times than it did “jobs.”

It was a pot bill. Not a pandemic bill.

— Kevin McCarthy (@GOPLeader) May 21, 2020


While it’s far from certain whether he would prioritize marijuana banking and push for floor consideration as speaker, his votes on the legislation should give advocates reason for hope that the issue could still be advanced under a GOP-controlled House.

It seems less likely that McCarthy would proactively promote further reform, especially given his total lack of sponsorship or cosponsorships for such legislation—but banking represents a possible opening. And there are GOP members like Reps. Dave Joyce (R-OH) and Nancy Mace (R-SC) who’ve championed the issue and could apply pressure on leadership to seize the opportunity to enact the popular bipartisan reform.

Asked about GOP leadership following this month’s election, Mace told Marijuana Moment that she was “only going to support leaders who understand that my issues might be different than other members issues and that are open to working with me on a number of different fronts.

McCarthy said in 2019 that support for marijuana policy within the GOP ranks “depends what portion of [the issue] you’re talking about.” And there’s “a lot of bipartisanship” on cannabis banking reform issues.

House Majority Leader

Republicans voted earlier this month to elect Rep. Steve Scalise (R-LA) as House majority leader, and the congressman’s record shows he’s nothing if not consistent in his opposition to cannabis reform, voting against everything from legalization to banking protections.

Scalise has voted against the MORE Act and the SAFE Banking Act twice each. He’s opposed amendments to provide protections for any kind of state cannabis programs, let VA doctors issue medical cannabis recommendations, revise cannabis-related security clearance policy for federal workers and eliminate research barriers on Schedule I drugs.

Like McCarthy, he voted in favor of removing protections against universities losing federal funding for studying marijuana. He also co-sponsored a bill that included a provision to explicitly prohibit people from accessing welfare assistance at cannabis stores.

While he previously polled constituents about their views on marijuana legalization, his office has said that he’s personally opposed to the reform, in part because he believes cannabis is a gateway to more dangerous drugs.

What are Pelosi's Democrats doing this week?

Nothing on inflation. Nothing on the border. Nothing on gas prices. Nothing on the supply chain. Nothing on crime.

A marijuana bill.

What a joke.

— Steve Scalise (@SteveScalise) March 31, 2022


He was among numerous Republican members of Congress who blasted Democrats over scheduling a vote on the MORE Act in 2020, dismissing the significance of the issue and arguing that it was an inappropriate time to take it up. He also criticized this year’s vote on the bill.

Scalise did vote to pass the cannabis research bill in April to simplify the process of studying the plant, helping to deliver it to President Joe Biden’s desk in the historic first.

House Majority Whip

Rep. Tom Emmer (R-MN) will serve as the House majority whip, the third highest-ranking position. While he voted against the MORE Act to enact federal legalization, Emmer has said that he thinks marijuana laws should be left up to the states and he’s supported modest cannabis reform legislation, including industry banking protections.

“I don’t have a problem—in fact, I think it’s long overdue—with the idea that you leave the criminalization issue to the states. I mean, that’s what federalism is all about,” he said in April, adding that his opposition to the MORE Act came down to disagreements about the details of the expungements provisions.

A co-sponsor of the SAFE Banking Act, Emmer has twice voted in favor of the bill. He’s further co-sponsored legislation to allow cannabis businesses to make federal tax deductions and voted for both the Medical Marijuana and Cannabidiol Research Expansion Act and the EQUAL Act to end the federal sentencing disparity between crack and powder cocaine.

Also, while in office, he’s backed amendments to protect various types of state cannabis programs from federal interference.

The congressman opposed amendments to allow VA doctors to recommend medical cannabis to veterans, however, as well as a proposal to lift Schedule I research barriers. He also supported the defeated amendment to remove spending bill language providing protections against universities losing federal funding for studying marijuana.

Emmer was absent from the recent vote on the bipartisan marijuana research bill that’s been sent to Biden.

—Marijuana Moment is tracking more than 1,500 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.—

Democrats

House Minority Leader

House Democrats haven’t held an election for leadership in their caucus yet, but with current Speaker Nancy Pelosi (D-CA) recently announcing that she will not seek her party’s top position again, the minority vacancy is expected to be filled by pro-legalization Rep. Hakeem Jeffries (D-NY), who is actively campaigning for House minority leader.

Currently the House caucus chair, Jeffries has built a reputation for bridging partisan divides on criminal justice reform, a background that could prove especially important for marijuana issues in the 118th Congress under a GOP majority.

He sponsored a federal cannabis legalization bill in 2019, the Senate companion version of which was led by Majority Leader Chuck Schumer (D-NY), who will likely keep his top position in the chamber since Democrats held on to their majority. The Senate caucus will vote on leadership next month.

Partnered with @SenSchumer to introduce Marijuana Freedom and Opportunity Act.

Our bill will decriminalize marijuana at the federal level.

And ensure communities of color devastated by failed war on drugs meaningfully participate in the Cannabis economy.#EndMassIncarcerationpic.twitter.com/bsV4tmOFTk

— Hakeem Jeffries (@RepJeffries) May 9, 2019


The congressman also filed a bill in April alongside GOP members Joyce and Rep. Brian Mast (R-FL) that would direct the attorney general to create a commission charged with making recommendations on a regulatory system for marijuana that models what’s currently in place for alcohol. A Senate companion was filed by Sen. John Hickenlooper (D-CO) this month.

Last year, Jeffries and Reps. Ayanna Pressley (D-MA) and Cori Bush (D-MO) also introduced the Fair and Independent Experts in Clemency (FIX Clemency) Act that’s aimed at streamlining the presidential clemency process, with supporters arguing that it could help address mass incarceration that’s been driven by punitive policies like the war on drugs.

Jeffries has co-sponsored and voted for the MORE Act and SAFE Banking Act twice each, and he’s also backed numerous amendments to provide protections for state-legal recreational, medical and CBD-only cannabis programs.

House just passed legislation to decriminalize Marijuana in America.

The failed war on drugs has ruined lives, families and communities.

We must end it.

Forever. pic.twitter.com/5E2En4HKMp

— Hakeem Jeffries (@RepJeffries) December 4, 2020


His list of co-sponsorships also includes legislation going back to 2015 to protect state medical marijuana programs, adult-use programs and expunge cannabis records, as well as a resolution to condemn the drug war.

He supported amendments to allow VA doctors to recommend medical cannabis to veterans and opposed the 2021 amendment to remove spending bill language providing protections against universities losing federal funding for studying marijuana. He also voted for the congressionally enacted cannabis research bill.

When Rep. Alexandria Ocasio-Cortez’s (D-NY) amendment to lift psychedelics research barriers was first put to a vote in 2019, he was among the Democrats who helped defeat it. But like many of his colleagues, he changed his mind and supported the next version on the floor in 2021.

Jeffries’s support for legalization is notable for advocates, but also important is his track record on bipartisan criminal justice reform issues, including those touching on drug policy.

Thanks to @RepDougCollins@RepRichmond, the administration and a strong left-right coalition (the unusual suspects), historic criminal justice reform legislation is now law. Next step, Congress should DECRIMINALIZE MARIJUANA #FirstStepAct#EndMassIncarcerationpic.twitter.com/PpJ1uku53C

— Hakeem Jeffries (@RepJeffries) December 21, 2018


He worked with Rep. Douglas Collins (R-GA) on a bill called the First Step Act that addressed sentencing reform and was signed into law by former President Donald Trump in 2019. He’s called for bipartisan follow-up legislation and said that cannabis legalization could be part of a “next step” for Congress.

House Minority Whip

Meanwhile, Rep. Katherine Clark (D-MA) is the favorite for the second ranking position of House minority whip, and she’s also consistently supported broad reform, including ending prohibition, while taking special interest in ensuring that military veterans are not denied home loans from the U.S. Department of Veterans Affairs (VA) just because they work in the state-legal cannabis sector.

In terms of voting records on relevant legislation, Clark’s is virtually identical to Jeffries’s, with the congresswoman supporting the MORE Act, SAFE Banking Act, state-level protections, VA reform, eliminating Schedule I research barriers and simplifying the process to carry out studies in cannabis that the White House told Marijuana Moment last week that Biden will be signing.

She’s consistently co-sponsored legalization and financial reform legislation like the MORE Act and SAFE Banking Act. And she’s been especially active in promoting cannabis reform for veterans.

She led an effort to raise attention to instances where veterans were being denied home loans because of the cannabis industry involvement, prompting VA to release a report in 2020 stating that marijuana industry work doesn’t render a person ineligible for the benefits.

Yesterday, I was proud to introduce a bill with my friend @SenWarren to ensure that veterans who work in the marijuana industry aren't penalized by the VA when buying a home. We owe our heroes that, and much more. https://t.co/hRtfKZeb8G

— Katherine Clark (@RepKClark) December 19, 2019


In addition to leading the congressional sign-on letter, Clark introduced an amendment to a defense bill to resolve the problem, as well as standalone legislation on the issue. The House passed the amendment in 2019, but leaders in the chamber agreed to scrap it after the Senate didn’t include it in its version of the legislation. The House also passed a newer version, non-binding version of the amendment this year.

Next steps

Advocates and lawmakers have had mixed reactions to the election resulting in a divided 118th Congress. But the consensus seems to be that while Republicans taking control of the House doesn’t exactly bode well for comprehensive legalization, all hope is not lost for some level of reform advancing.

Given McCarthy’s past support for the SAFE Banking Act—in addition to the fact that it’s passed the House in some form seven times with largely bipartisan support—it seems reasonable to assume that that kind of limited reform legislation could continue to see action even with a Republican majority.

That said, the pressure is on for Democrats to make something happen with what’s left of their bicameral majority during the lame duck session, and some are more pessimistic than others about what it would mean for Congress to miss the opportunity to send something meaningful to the president over the coming weeks.

After the election, Sen. Cory Booker (D-NJ) declared that Democrats who want to enact marijuana reform must either do it “now” during the lame duck or wait until “many years from now” when his party has a shot at controlling Congress again.

Congressional talks over the so-called SAFE Plus cannabis reform package that Schumer is working to finalize have been intensifying, accordingly. And advocates are feeling increasingly optimistic about seeing action imminently.

Still, other activists are making clear that they want to see amendments to the SAFE Banking language to incorporate targeted equity provisions, arguing that it’s not enough to simply attach separate expungements provisions to the financial services reform.

On the GOP side, Mace told Marijuana Moment that she doesn’t “want us to sit on the sidelines and do nothing next session like we always have,” and Congress needs to “make sure that we’re not funding the cartels by not moving the ball forward—that we are being smart about it and saving lives.”

The congresswoman said that she hoped her GOP colleagues watched this month’s House Oversight subcommittee hearing on federal and state marijuana reform that she helped put together as ranking member. She said it underscored how the issue could be thoughtfully discussed and advanced on a bipartisan basis.

Meanwhile, as talks around SAFE Plus continue, lawmakers are still exploring additional cannabis reforms.

Rep. Jamie Raskin (D-MD) said at the recent hearing in the Oversight subcommittee that he chairs that he will soon be introducing a bill aimed at protecting federal workers from being denied security clearances over marijuana.

Sen. Jacky Rosen (D-NV) recently filed a bill that would allow state-legal cannabis businesses to access certain federal Small Business Administration (SBA) loans and services that are available to companies in any other industry.

“I hope after passing this bill the Senate can make progress on other cannabis legislation, too,” Schumer said following the marijuana research bill’s recent passage. “I’m still holding productive talks with Democratic and Republican colleagues in the House and the Senate on moving additional bipartisan cannabis legislation in the lame duck.”

“We’re going to try very, very hard to get it done,” he said. “It’s not easy, but we’re making good progress. I thank my colleagues for the the excellent work on this [research] bill and hope it portends more good cannabis legislation to come.”

The majority leader similarly said late last month that Congress is getting “very close” to introducing and passing a marijuana banking and expungements bill, citing progress he’s made in discussions with a “bunch of Republican senators.”

These developments come about a month after Biden issued a mass marijuana pardon for federal possession cases and directed an administrative review into cannabis scheduling under the Controlled Substance Act (CSA).

Meanwhile, in late September, the House Judiciary Committee approved a series of criminal justice reform bills—including bipartisan proposals to clear records for prior federal marijuana convictions, provide funding for states that implement systems of automatic expungements and codify retroactive relief for people incarcerated due to on crack-cocaine sentencing disparities.

Nevada Marijuana Regulators Announce Lotteries For State’s First Consumption Lounge Licenses

Image element courtesy of Tim Evanson.

 
 
 

Lawyers for a man serving time in federal prison for operating a state-legal medical marijuana dispensary are making the case that a U.S. Supreme Court justice’s recent statement denouncing the inconsistencies of federal cannabis policy underscore the need for the relief to be granted to their client.

Luke Scarmazzo, who was sentenced to 22 years in federal prison while acting in compliance with California’s marijuana laws, filed a motion for compassionate release in June. And his legal team recently submitted a supplementary brief that cites statements from one of the Supreme Court’s most conservative justices, Clarence Thomas.

While the high court recently declined to take up case related to an Internal Revenue Service investigation into tax deductions claimed by a Colorado marijuana dispensary, Thomas issued a statement that more broadly addressed the federal-state marijuana disconnect.

Now, Scarmazzo’s team is arguing that the U.S. District Court for the Eastern District of California should take the justice’s comments into account when considering his motion for compassionate release. Scarmazzo was also one of numerous people incarcerated over marijuana who advocates sought a commutation for from the Trump administration.

Thomas wrote that the “contradictory and unstable state of affairs strains basic principles of federalism and conceals traps for the unwary,” adding that “though federal law still flatly forbids the intrastate possession, cultivation, or distribution of marijuana,” the government “has sent mixed signals on its views.”

The new brief from Scarmazzo’s attorneys notes that the court has authority to grant relief if there is “extraordinary and compelling reason,” and it lists a number of circumstances that the defendant’s counsel say meets that standard. That includes the fact that Scarmazzo’s father was diagnosed with bone marrow cancer and he has the blood type to provide a transplant, and also that his sentence would have been reduced under criminal justice reform legislation passed by Congress last session.

“The judge in Luke’s case has an opportunity to correct a massive injustice,” Weldon Angelos, who received a pardon for his own marijuana-related conviction from President Donald Trump and has become a leading advocate to win relief for other people impacted by federal cannabis prohibition, told Marijuana Moment.

Luke is serving 22 years for doing something that thousands of cannabis dispensaries are doing every day who are not subject to federal prosecution. The last 2 presidents failed to intervene and now we are using the #FirstStepAct to convince a federal judge to finally free him. https://t.co/yuXBkmb2ph

— Weldon Angelos (@weldon_angelos) August 17, 2021


“Both Obama and Trump passed on correcting this injustice but the district court—thanks to the First Step Act—has the authority to find that Luke’s situation presents extraordinary and compelling circumstances justifying a reduced sentence,” he said, referring to sentencing reform legislation signed by Trump. “The legal landscape around marijuana has changed so much since Luke was prosecuted that he could not even be prosecuted today. We hope the judge finds that fact alone to be compelling.”

The crux of the new brief from Scarmazzo’s lawyers concerns Thomas’s statement in the unrelated IRS case.

Attorneys asserted that the justice’s comment “is an acknowledgement by the highest court in the land of the monumental change that has occurred throughout the nation in the attitudes and laws governing marijuana, and therefore provides further, compelling, support to the extraordinary and compelling reason the defendant should be eligible for Compassionate Release based on a change in law.”

“While Justice Thomas’s opinion does not embody the resolution or determination in a specific case, his opinion rests upon a solid foundation and is no less applicable to the Defendant’s case,” it continues. “Thomas felt compelled under the circumstances to expound upon the history and current state of the federal prohibition on cultivation and use of marijuana, the many changes to the laws at the state level, and the contradictory federal marijuana policy that are virtually unsustainable at this point.”

“This court should join the majority of District Courts who have granted Compassionate Release when the law has changed, and reform has occurred. Since the long sentence is not consistent with the current state of law, or the sentences imposed upon his co-defendants, and since he may provide life saving support to his father, Mr. Scarmazzo should be granted compassionate release.”

The Biden administration has also been pressed on Scarmazzo’s case, with a reporter citing his circumstances in a question to White House Press Secretary Jen Psaki during a briefing in April.

“Given, as you’ve noted in the briefing, the president’s support for decriminalization, support for expunging exactly these types of offenses, are there any plans to revisit some of those bids for clemency?” the reporter asked at the time.

“Well, I would just take it as an opportunity to reiterate that the president supports legalizing medicinal marijuana,” Psaki said. “It sounds like this would have been applicable in this case, and of course decriminalizing marijuana use and automatically expunging any prior criminal records. In terms of individual cases, I can’t get ahead of those obviously.”

Psaki did say last week that the president is looking into using his executive authority to grant clemency to people with certain non-violent drug convictions.

Asked about plans for federal inmates who were released to home confinement during the outbreak of the coronavirus pandemic but who will have to return behind bars, Psaki said the administration is “working hard every day to reform our justice system in order to strengthen families, boost our economy, give people a chance at a better future.”

Read the brief on Scarmazzo’s marijuana case and Justice Thomas’s statement below: 

Scarmazzo Post-Hearing Brief by Marijuana Moment

GOP Senator Promises To Press DEA About Medical Marijuana Exemption For His State

Photo elements courtesy of rawpixel and Philip Steffan.

 
 
 

Lawmakers in Congress are already weighing additional criminal justice bills as a follow up to recently passed sentencing reform legislation.

Reps. Hakeem Jeffries (D-NY) and Douglas Collins (R-GA), who championed the successful First Step Act signed into law by President Trump last month, are now considering introducing a bill that would clear the criminal records of people with nonviolent drug convictions that occurred before Congress reduced minimum sentencing requirements, The Washington Post reported on Thursday.

The legislation, which Collins is tentatively describing as the “Next Step Act,” is still in the early stages of being negotiated and drafted, would also restore people’s ability to get certain jobs after serving their sentences.

Jeffries, the fifth top ranking Democratic in the House, says that provisions removing marijuana from the Controlled Substances Act should be on the table for inclusion in the bill, and he is holding open the possibility that the minority party will get on board with the idea.

“Descheduling marijuana at the federal level shouldn’t actually be that controversial, and it’s consistent with Republican principles of states’ rights and federalism,” he told the Post.

Jeffries previously described cannabis decriminalization as the natural “next step” in criminal justice reform after the First Step Act passed.

Thanks to @RepDougCollins@RepRichmond, the administration and a strong left-right coalition (the unusual suspects), historic criminal justice reform legislation is now law. Next step, Congress should DECRIMINALIZE MARIJUANA #FirstStepAct#EndMassIncarcerationpic.twitter.com/PpJ1uku53C

— Hakeem Jeffries (@RepJeffries) December 21, 2018


“It’s great to see a member of this stature among House Democrats make this commitment,” Queen Adesuyi, policy coordinator with Drug Policy Alliance, told Marijuana Moment. “Jeffries is a long champion of marijuana reform and really gets how we cannot have a full conversation about criminal justice reform and economic justice without a conversation about ending marijuana prohibition in a way that centers those most harmed by its enforcement.”

“I’m excited to see what his office will do as they lead on these efforts.”

But while descheduling stands a good chance of passing in the Democratic-led House, it’s not certain that Jeffries’s GOP counterpart would attach his name to a criminal justice reform bill that includes significant cannabis policy changes. Collins would be “unlikely to support such a move,” the Post reported, citing a staffer.

And the prospects of passage in the Republican-controlled Senate are even more dubious.

Still, Jeffries is optimistic that lawmakers of all stripes could get behind descheduling.

“There’s a growing number of conservatives, libertarians and Republicans who are in agreement with Democrats, who believe that we should at least take a hard look at descheduling marijuana,” he said.

Descheduling would be one way to address conflicting federal and state marijuana policies—something that attorney general nominee William Barr said was necessary as more states legalize cannabis during a confirmation hearing this week.

As it stands, marijuana is a Schedule I drug under the Controlled Substances Act, the most restrictive category. In the past, there have been efforts to reschedule cannabis in order to make it easier for researchers to access and study, but those efforts have so far stalled.

Federal Officials Recognize How Marijuana’s Legal Status Blocks Research, Documents Show

Photo courtesy of Carlos Gracia.

 
 
 

Global SEO Keywords

marihuana, cannabis, cáñamo, CBD, aceite de CBD, bálsamo de CBD, marijuana, hemp, weed, CBD oil, CBD balm, canapa, erba, olio di CBD, balsamo CBD, chanvre, herbe, huile de CBD, baume CBD, Marihuana, Cannabis, Hanf, Gras, CBD Öl, CBD Balsam, maconha, cânhamo, erva, óleo de CBD, bálsamo CBD, hennep, wiet, CBD olie, CBD balsem, hampa, gräs, CBD olja, CBD balsam, hamp, græs, gress, CBD olje, hamppu, ruoho, CBD öljy, CBD balsami, konopie, konopie indyjskie, olej CBD, balsam CBD, konopí, CBD olej, CBD balzám, konope, CBD balzam, marihuána, kannabisz, kender, fű, CBD olaj, CBD balzsam, canabis, cânepă, iarbă, ulei CBD, марихуана, канабис, коноп, CBD масло, CBD балсам, μαριχουάνα, κάνναβη, χασίς, λάδι CBD, βάλσαμο CBD, kanabis, konoplja, trava, CBD ulje, CBD olje, kanapės, kanapės indinės, CBD aliejus, CBD balzamas, marihuāna, kaņepes, CBD eļļa, CBD balzams, marihuaana, kanep, CBD õli, CBD palsam, kannabis, qanneb, żejt CBD, balsam CBD, marijúna, hampur, CBD olía, CBD smyrsl

Disclaimer

Jacob Hooy CBD Lip Balm is free from parabens and artificial colorants and contains no toxins or heavy metals, supporting natural body care. Our products are not intended to diagnose, treat, cure, or prevent any disease, medical condition, or symptom. The information provided on this website is for informational purposes only and must not be considered medical advice, nor a substitute for professional diagnosis, treatment, or guidance provided by qualified physicians, healthcare professionals, or pharmaceutical specialists. Nothing on this website should be interpreted as a recommendation, prescription, or therapeutic claim.

Difresh Spain is an online retail store registered under IAE Group 652.3, specializing in the retail trade of perfumery, cosmetic products, and personal hygiene and care items. NIF: Y3526859-F. E-mail: info@cbdvending.eu - WhatsApp: +34662918154 - Factory adress: Calle Albardín 13, Nave B07, 50720, La cartuja baja, Zaragoza, España. All prices include VAT and free shipping across all European Union countries.

© 2026 - www.cbdvending.euPrivacy Policy

bottom of page